CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - "AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX FOR INJECTION" OBTAINS DRUG REGISTRATION APPROVAL

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC PHARMACEUTICAL GROUP LIMITED

石 藥 集 團 有 限 公 司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

"AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX FOR INJECTION" OBTAINS DRUG REGISTRATION APPROVAL

The board of directors (the "Board") of CSPC Pharmaceutical Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the "Amphotericin B Cholesteryl Sulfate Complex For Injection (50mg)" (the "Product") developed by CSPC Ouyi Pharmaceutical Co., Ltd.*（石藥集團歐意藥業有限公司）, a subsidiary of the Company, has obtained drug registration approval granted by the National Medical Products Administration of the People's Republic of China, being the first-to-market generic of this product type in China.

Amphotericin B is a type of polyene antibiotic, and is one of the most effective drugs with the broadest antimicrobial spectrum for prevention and treatment of invasive fungal infections. The Product is indicated for the treatment of patients with invasive fungal infections, patients where renal impairment or drug toxicity precludes the use of effective dose of amphotericin B or patients fail in prior amphotericin B deoxycholate treatment. Comparing with amphotericin B for injection used in clinical practice in China, the Product could significantly decrease nephrotoxicity and increase dosage, thus enhancing the therapeutic index. The approval of the Product will enable more patients to have chances to get treated or cured, hence having a better survival prognosis.

The approval of the Product will further diversify the Group's product portfolio, representing a significant breakthrough of the Group in the field of invasive fungal infection treatment.

- 1 -

By Order of the Board

CSPC Pharmaceutical Group Limited

Cai Dongchen

Chairman

Hong Kong, 1 April 2021

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.

*  For identification purpose only

- 2 -